Evidence map›Paper›PMID 40147634›Full record

ArticleJournal of lipid research2025

Lecithin:cholesterol acyltransferase binds a discontinuous binding site on adjacent apolipoprotein A-I belts in HDL.

Bethany Coleman, Shimpi Bedi, John H Hill, Jamie Morris, Kelly A Manthei, Rachel C Hart, Yi He, Amy S Shah, W Gray Jerome, Tomas Vaisar and 7 more

Abstract read
In one paragraph

Article in Journal of lipid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bethany ColemanDepartment of Molecular and Cellular Biosciences, University of Cincinnati, Cincinnati, OH, USA.
Shimpi BediDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA.
John H HillDepartment of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jamie MorrisDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA.
Kelly A MantheiLife Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
Rachel C HartDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Yi HeDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Amy S ShahDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, USA.
W Gray JeromeDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Tomas VaisarDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Karin E BornfeldtDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Hyun SongDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Jere P SegrestDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Jay W HeineckeDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Stephen G AllerDepartment of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.
John J G TesmerDepartments of Biological Sciences and Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.
W Sean DavidsonDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA. Electronic address: Sean.Davidson@UC.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON · 1986 to 2026
$30.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Project 3 - HDL Structure/Function in LCAT Deficient HumansP01HL128203 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI W Sean Davidson · 2016 to 2026
$25.1M
Non-coding RNA & Bioinformatics CoreP01HL116263 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LINTON, MACRAE F · 2014 to 2025
$24.7M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Structure, function, and inhibition of G protein-coupled receptor kinasesR01HL071818 · NHLBI · UNIVERSITY OF TEXAS AUSTIN · PI TESMER, JOHN · 2004 to 2023
$7.1M
Identifying new strategies for prevention of cardiovascular complications of diabetesR35HL150754 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E · 2020 to 2025
$6.2M
NCI NIH HHS P30 CA023168NCI NIH HHS P30 CA068485NEI NIH HHS P30 EY008126NHLBI NIH HHS F32 HL131288NHLBI NIH HHS P01 HL116263NHLBI NIH HHS P01 HL128203NHLBI NIH HHS R01 HL071818NHLBI NIH HHS R01 HL122416NHLBI NIH HHS R01 HL153118NHLBI NIH HHS R01 HL155601NHLBI NIH HHS R35 HL150754NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK035816NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637
6 · The paper itself

Abstract

Lecithin:cholesterol acyltransferase (LCAT) is a high-density lipoprotein (HDL) modifying protein that profoundly affects the composition and function of HDL subspecies. The cholesterol esterification activity of LCAT is dramatically increased by apolipoprotein A-I (APOA1) on HDL, but the mechanism remains unclear. Using site-directed mutagenesis, cross-linking, mass spectrometry, electron microscopy, protein engineering, and molecular docking, we identified two LCAT binding sites formed by helices 4 and 6 from two antiparallel APOA1 molecules in HDL. Although the reciprocating APOA1 "belts" form two ostensibly symmetrical binding locations, LCAT can adopt distinct orientations at each site, as shown by our 9.8 Å cryoEM envelope. In one case, LCAT membrane binding domains align with the APOA1 belts and, in the other, the HDL phospholipids. By introducing disulfide bonds between the APOA1 helical domains, we demonstrated that LCAT does not require helical separation during its reaction cycle. This indicates that LCAT, anchored to APOA1 belts, accesses substrates and deposits products through interactions with the planar lipid surface. This model of the LCAT/APOA1 interaction provides insights into how LCAT and possibly other HDL-modifying factors engage the APOA1 scaffold, offering potential strategies to enhance LCAT activity in individuals with genetic defects.

Indexed as

Apolipoprotein A-ILipoproteins, HDLPhosphatidylcholine-Sterol O-AcyltransferaseBinding SitesHumansMolecular Docking SimulationProtein BindingAPOA1 protein, humanApolipoprotein A-ILCAT protein, humanLipoproteins, HDLPhosphatidylcholine-Sterol O-Acyltransferaseapolipoproteinapolipoprotein A-Icholesterol esterificationcross-linkingcryo-electron microscopydockingHDLLCATlecithin:cholesterol acyltransferasemass spectrometrymutagenesisstructure

Identifiers

PMID40147634
PMCPMC12049944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.